IL264112A - An a3 adenosine receptor ligand for use for reducing level of adipocytes - Google Patents

An a3 adenosine receptor ligand for use for reducing level of adipocytes

Info

Publication number
IL264112A
IL264112A IL264112A IL26411219A IL264112A IL 264112 A IL264112 A IL 264112A IL 264112 A IL264112 A IL 264112A IL 26411219 A IL26411219 A IL 26411219A IL 264112 A IL264112 A IL 264112A
Authority
IL
Israel
Prior art keywords
adipocyte
adenosine
lowering
levels
receptor ligand
Prior art date
Application number
IL264112A
Other languages
English (en)
Hebrew (he)
Inventor
Fishman Pnina
Farbstein Motti
Itzhak Inbal
Cohen Shira
Original Assignee
Fishman Pnina
Can Fite Biopharma Ltd
Farbstein Motti
Itzhak Inbal
Cohen Shira
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fishman Pnina, Can Fite Biopharma Ltd, Farbstein Motti, Itzhak Inbal, Cohen Shira filed Critical Fishman Pnina
Priority to IL264112A priority Critical patent/IL264112A/en
Priority to JP2021539140A priority patent/JP2022517753A/ja
Priority to MX2021008172A priority patent/MX2021008172A/es
Priority to AU2020205042A priority patent/AU2020205042B2/en
Priority to EP20700855.8A priority patent/EP3906034A1/en
Priority to US17/309,952 priority patent/US12213990B2/en
Priority to CN202080008167.6A priority patent/CN113543790A/zh
Priority to BR112021013084-5A priority patent/BR112021013084A2/pt
Priority to CA3126002A priority patent/CA3126002A1/en
Priority to IL284463A priority patent/IL284463B1/en
Priority to KR1020217024682A priority patent/KR20210113279A/ko
Priority to PCT/IL2020/050011 priority patent/WO2020141535A1/en
Publication of IL264112A publication Critical patent/IL264112A/en
Priority to JP2023078136A priority patent/JP2023100928A/ja
Priority to JP2025049941A priority patent/JP2025098147A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL264112A 2019-01-06 2019-01-06 An a3 adenosine receptor ligand for use for reducing level of adipocytes IL264112A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IL264112A IL264112A (en) 2019-01-06 2019-01-06 An a3 adenosine receptor ligand for use for reducing level of adipocytes
BR112021013084-5A BR112021013084A2 (pt) 2019-01-06 2020-01-05 Ligante do receptor de adenosina a3 (a3ar) para uso na obtenção de pelo menos um efeito de perda de gordura, composição farmacêutica, método para tratar um indivíduo, e kit
CA3126002A CA3126002A1 (en) 2019-01-06 2020-01-05 An a3 adenosine receptor ligand for use for achieving a fat loss effect
AU2020205042A AU2020205042B2 (en) 2019-01-06 2020-01-05 An A3 adenosine receptor ligand for use for achieving a fat loss effect
EP20700855.8A EP3906034A1 (en) 2019-01-06 2020-01-05 An a3 adenosine receptor ligand for use for achieving a fat loss effect
US17/309,952 US12213990B2 (en) 2019-01-06 2020-01-05 A3 adenosine receptor ligand for use for achieving a fat loss effect
CN202080008167.6A CN113543790A (zh) 2019-01-06 2020-01-05 用于实现减脂效果的用途的a3腺苷受体配体
JP2021539140A JP2022517753A (ja) 2019-01-06 2020-01-05 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド
MX2021008172A MX2021008172A (es) 2019-01-06 2020-01-05 Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso.
IL284463A IL284463B1 (en) 2019-01-06 2020-01-05 Adenosine 3A receptor ligand for use in reducing adipocyte levels
KR1020217024682A KR20210113279A (ko) 2019-01-06 2020-01-05 지방 손실 효과를 달성하는데 사용하기 위한 a3 아데노신 수용체 리간드
PCT/IL2020/050011 WO2020141535A1 (en) 2019-01-06 2020-01-05 An a3 adenosine receptor ligand for use for achieving a fat loss effect
JP2023078136A JP2023100928A (ja) 2019-01-06 2023-05-10 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド
JP2025049941A JP2025098147A (ja) 2019-01-06 2025-03-25 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL264112A IL264112A (en) 2019-01-06 2019-01-06 An a3 adenosine receptor ligand for use for reducing level of adipocytes

Publications (1)

Publication Number Publication Date
IL264112A true IL264112A (en) 2020-07-30

Family

ID=65656120

Family Applications (2)

Application Number Title Priority Date Filing Date
IL264112A IL264112A (en) 2019-01-06 2019-01-06 An a3 adenosine receptor ligand for use for reducing level of adipocytes
IL284463A IL284463B1 (en) 2019-01-06 2020-01-05 Adenosine 3A receptor ligand for use in reducing adipocyte levels

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL284463A IL284463B1 (en) 2019-01-06 2020-01-05 Adenosine 3A receptor ligand for use in reducing adipocyte levels

Country Status (11)

Country Link
US (1) US12213990B2 (https=)
EP (1) EP3906034A1 (https=)
JP (3) JP2022517753A (https=)
KR (1) KR20210113279A (https=)
CN (1) CN113543790A (https=)
AU (1) AU2020205042B2 (https=)
BR (1) BR112021013084A2 (https=)
CA (1) CA3126002A1 (https=)
IL (2) IL264112A (https=)
MX (1) MX2021008172A (https=)
WO (1) WO2020141535A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300014340A1 (it) * 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
DE69428536T2 (de) 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CN101410114B (zh) 2006-01-26 2012-07-04 美国政府卫生与公共服务部 A3腺苷受体别构调节剂
EP2608794A4 (en) * 2010-08-26 2014-01-22 Univ Northeastern METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING OIL CONTAINER
CN104159589A (zh) 2012-01-23 2014-11-19 坎-菲特生物药物有限公司 肝脏状况的治疗
IL242723B (en) * 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR101881441B1 (ko) 2017-01-20 2018-07-24 서울대학교산학협력단 다중 약리단 특성에 기반한 비정상적 아디포넥틴 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
WO2020141535A1 (en) 2020-07-09
JP2023100928A (ja) 2023-07-19
IL284463B1 (en) 2026-04-01
IL284463A (en) 2021-08-31
JP2022517753A (ja) 2022-03-10
KR20210113279A (ko) 2021-09-15
CA3126002A1 (en) 2020-07-09
EP3906034A1 (en) 2021-11-10
JP2025098147A (ja) 2025-07-01
MX2021008172A (es) 2021-08-11
AU2020205042A1 (en) 2021-07-15
US20220079968A1 (en) 2022-03-17
AU2020205042B2 (en) 2024-10-10
CN113543790A (zh) 2021-10-22
US12213990B2 (en) 2025-02-04
BR112021013084A2 (pt) 2021-09-21

Similar Documents

Publication Publication Date Title
IL284492B (en) Beam information in early measurements
EP4069686C0 (en) GLP-1 RECEPTOR AGONIST
EP3976075A4 (en) MODIFIED ADENOVIRUS
SI3394094T1 (sl) T celični receptorji, specifični za NY-ESO-1 tumorski kompleks antigen-HLA-A*02
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
EP3808228A4 (en) REMOVABLE CARPET
EP3820348C0 (en) DISHWASHER WITH HEIGHT-ADJUSTABLE BASKET ARRANGEMENT
DK3826513T3 (da) Demonterbar gulvmåtte
EP3755296C0 (en) SEAT SUPPORT
IL277744A (en) Pyrazolotriazolopyrimidine derivatives as A2A receptor inhibitors
LT3914600T (lt) Tiazolopiridino dariniai kaip adenozino receptoriaus antagonistai
IL289841A (en) A3 adenosine receptor ligand for use in the treatment of ectopic fat accumulation
DK3334721T3 (da) Cgrp-receptorantagonister
DK3917538T3 (da) Deoxycytidinderivater til anvendelse i cancerterapier
IL284981A (en) Semaphorin-4d antagonists for use in cancer therapy
IL284463A (en) An a3 adenosine receptor ligand for use for achieving a fat loss effect
DK3581572T3 (da) Adenosin-A3-receptormodulatorer
DK3242680T3 (da) Interleukin-1-receptorantagonist til anvendelse i behandling af cystitis
DK3297979T3 (da) Forbindelser og fremgangsmåder til at modulere serotoninreceptorer i periferien
EP3626671C0 (en) BOTTOM BLOCK ASSEMBLY
DK3372749T3 (da) Gulvplankesystem
DK3315689T3 (da) Justerbart gulvstøttesystem
IL287508A (en) Indole compounds for use in neurorestoration
EP4061124A4 (en) TRPV4 RECEPTOR LIGANDS
CA188570S (en) Measuring wedge for use in placing tiles